Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TYMP | P19971 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TK1 | P04183 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9155069 | 0.84 | TYMP (0.43) | MAPK1HPGDTYMPALDH1A1LMNA | |
| SCHEMBL22759941 | 0.84 | MAPK1 (0.41) | MAPK1HPGDTYMPALDH1A1LMNA | |
| SCHEMBL4194708 | 0.84 | MAPK1 (0.41) | MAPK1HPGDTYMPALDH1A1LMNA | |
| SCHEMBL13310896 | 0.82 | MAPK1 (0.42) | MAPK1HPGDTYMPALDH1A1LMNA | |
| SCHEMBL6153438 | 0.81 | MAPK1 (0.42) | MAPK1HPGDTYMPALDH1A1LMNA | |
| SCHEMBL22381003 | 0.81 | ALDH1A1 (0.43) | MAPK1HPGDTYMPALDH1A1LMNA | |
| SCHEMBL21511226 | 0.81 | MAPK1 (0.39) | MAPK1HPGDTYMPALDH1A1LMNA | |
| SCHEMBL24529716 | 0.80 | MET (0.34) | ALDH1A1POLBMETSMN1; SMN2 | |
| SCHEMBL22571159 | 0.80 | ALDH1A1 (0.34) | HPGDALDH1A1POLBMETTK1 | |
| SCHEMBL8656137 | 0.80 | SMN1; SMN2 (0.38) | MAPK1HPGDTYMPALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043637-B2 | Fluorescent dyes containing bis-boron fused heterocycles and uses in sequencing | ILLUMINA CAMBRIDGE LIMITED (GB) | 2024-07-23 | — | — | US | disclosed |
| US-12031179-B2 | Methods and compositions for reducing nucleotide impurities | Singular Genomics Systems, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12031179-B2 | Methods and compositions for reducing nucleotide impurities | Singular Genomics Systems, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030911-B2 | Synthesis and biological activity of phosphoramidimidate and phosphoramidate DNA | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030911-B2 | Synthesis and biological activity of phosphoramidimidate and phosphoramidate DNA | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240209015-A1 | METHODS OF SEQUENCING USING 3' BLOCKED NUCLEOTIDES | ILLUMINA, INC. | 2024-06-27 | — | — | US | disclosed |
| WO-2023249905-A1 | COMPOSITIONS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS | HONGENE BIOTECH CORPORATION (US) | 2023-12-28 | — | — | WO | disclosed |
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-20230381216-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230381216-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-7507859-B2 | Functional synthetic molecules and macromolecules for gene delivery | FIFTH BASE LLC (US) | 2009-03-24 | — | — | US | disclosed |
| US-20080207554-A1 | 2-5A Analogs and their Methods of Use | ALIOS BIOPHARMA, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080193452-A1 | Therapeutic Compounds Derived from Spider Venom and Their Method of Use | CORNELL RESEARCH FOUNDATION, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-7405214-B2 | Nucleoside derivatives and therapeutic use thereof | REXAHN CORPORATION (US) | 2008-07-29 | — | — | US | disclosed |
| US-7339054-B2 | Process for preparing branched ribonucleosides from 1,2-anhydroribofuranose intermediates | MERCK & CO., INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7339054-B2 | Process for preparing branched ribonucleosides from 1,2-anhydroribofuranose intermediates | MERCK & CO., INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-20070232636-A1 | Substituted Diaza-Spiro-[5.5]-Undecane Derivaties and Their Use as Neurokinin Antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-04 | — | — | US | disclosed |
| US-20070196834-A1 | Method and system for the generation of large double stranded DNA fragments | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2007-08-23 | — | — | US | disclosed |
| US-20070037771-A1 | Reacting 2-Anhydro-3,5-di-O-(p-toluoyl)-2-C-methyl- alpha -D-ribofuranose with nucleophile such as cytosine, uracil, thymine, hypoxanthine, adenine, guanine, 7-deazaguanine, 7-deazaadenine, 7-deaza-2,6-diaminopurine, and 7-deazahypoxanthine, removing hydroxyl protecting groups | MERCK SHARP & DOHME CORP. | 2007-02-15 | — | — | US | disclosed |
| US-20070037771-A1 | Reacting 2-Anhydro-3,5-di-O-(p-toluoyl)-2-C-methyl- alpha -D-ribofuranose with nucleophile such as cytosine, uracil, thymine, hypoxanthine, adenine, guanine, 7-deazaguanine, 7-deazaadenine, 7-deaza-2,6-diaminopurine, and 7-deazahypoxanthine, removing hydroxyl protecting groups | MERCK SHARP & DOHME CORP. | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030911-B2 | Synthesis and biological activity of phosphoramidimidate and phosphoramidate DNA | RNASEH1, RNASE1, DNASE1 | MAPK1 2737/4885HPGD 3354/4885TYMP 22/4885 |
| US-20080193452-A1 | Therapeutic Compounds Derived from Spider Venom and Their Method of Use | ADAR, FUT5, CSGALNACT1 | MAPK1 3683/4885HPGD 2467/4885TYMP 289/4885 |
| US-12043637-B2 | Fluorescent dyes containing bis-boron fused heterocycles and uses in sequencing | BLVRB, BCDIN3D, FOSB | MAPK1 3792/4885HPGD 3273/4885TYMP 481/4885 |
| US-20070232636-A1 | Substituted Diaza-Spiro-[5.5]-Undecane Derivaties and Their Use as Neurokinin Antagonists | NPSR1, PROKR2, KISS1R | MAPK1 2809/4885HPGD 1087/4885TYMP 4442/4885 |
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | MAPK1 142/4885HPGD 3084/4885TYMP 2290/4885 |
| US-20230381216-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | UTRN, SMN1; SMN2, DCLRE1B | MAPK1 4796/4885HPGD 4713/4885TYMP 2220/4885 |
| US-20070037771-A1 | Reacting 2-Anhydro-3,5-di-O-(p-toluoyl)-2-C-methyl- alpha -D-ribofuranose with nucleophile such as cytosine, uracil, thymine, hypoxanthine, adenine, guanine, 7-deazaguanine, 7-deazaadenine, 7-deaza-2,6-diaminopurine, and 7-deazahypoxanthine, removing hydroxyl protecting groups | DUT, RNGTT, DPYD | MAPK1 3075/4885HPGD 554/4885TYMP 13/4885 |
| US-20080207554-A1 | 2-5A Analogs and their Methods of Use | RNASEL, RNASE1, RNASEH1 | MAPK1 4161/4885HPGD 1954/4885TYMP 139/4885 |
| US-20240209015-A1 | METHODS OF SEQUENCING USING 3' BLOCKED NUCLEOTIDES | RNGTT, NT5C3B, NSUN2 | MAPK1 3019/4885HPGD 2977/4885TYMP 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.